What Are the Main Risks and Opportunities in Merck's Cholesterol Drug Franchise?
The Motley Fool's health-care show Market Checkup focuses this week on cholesterol, one of America's most notable health-care concerns.
According to the CDC, approximately 71 million Americans have high cholesterol, and less than 50% actually get treated. High levels of LDL cholesterol, commonly known as "bad" cholesterol, can lead to dangerous health problems, including heart disease and high blood pressure. In the following segment, health-care analysts David Williamson and Max Macaluso discuss Dow component Merck's portfolio of cholesterol-lowering drugs, and how an ongoing clinical study could lower sales of one of its most successful franchises.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article What Are the Main Risks and Opportunities in Merck's Cholesterol Drug Franchise? originally appeared on Fool.com.David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.